Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
about
Janus kinases in immune cell signalingPromising new treatments for psoriasisJakpot! New small molecules in autoimmune and inflammatory diseasesGenetics of SCIDMS-1020 is a novel small molecule that selectively inhibits JAK3 activity.NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3chinmo is a functional effector of the JAK/STAT pathway that regulates eye development, tumor formation, and stem cell self-renewal in DrosophilaFuture therapeutic targets in rheumatoid arthritis?Innate immune regulation by STAT-mediated transcriptional mechanisms.Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.Combined immunodeficiency evolving into predominant CD4+ lymphopenia caused by somatic chimerism in JAK3Kinase inhibitors in the treatment of immune-mediated diseaseSevere combined immunodeficiency (SCID): from the detection of a new mutation to preimplantation genetic diagnosisBD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathwayThe use of structural biology in Janus kinase targeted drug discovery.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesOverview of the immune response.Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.New JAK2 inhibitors for myeloproliferative neoplasms.Small molecular therapies for rheumatoid arthritis: where do we stand?Proposal for a new nomenclature of disease-modifying antirheumatic drugs.Therapeutic targeting of the Jak/STAT pathway.Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.Jak3 deficiency blocks innate lymphoid cell development.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties.Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.A reversion of an IL2RG mutation in combined immunodeficiency providing competitive advantage to the majority of CD8+ T cellsSelective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.Efficacy of tofacitinib in treatment of alopecia universalis in two patients.
P2860
Q24322021-E4ECBE91-82F2-404E-9B78-B0169A04FEF3Q24598008-A08F0FCF-22B8-44D6-8B2E-AF6FF26ED6D6Q27001957-1E886286-14AE-4C65-8007-F8DB288A9813Q27499229-DBD3C3C8-C37D-44BF-9A8D-0EADD7E9D3E0Q33507716-5D3EE297-E6A2-46E6-A2DB-C9AE4059F60DQ33530722-0221D390-F580-46EE-A879-02CD03C2C237Q33808684-62723177-B7EA-4894-9E5C-D5CA67CC1DF7Q33841419-21C1BF08-A2D6-4EC4-A2AE-01332E3D0F3CQ34055968-D39117D0-3363-4066-B58F-8803427046E9Q34084020-DE16ABB0-CED4-4816-A5C5-2B59A4C047DEQ34452150-AC9E820E-9FEB-4CBC-BD56-BDE4A66F45A0Q35814037-7B5EFB2D-6A54-4417-9C1C-30B16E4FED1DQ36106410-4DFC0846-B890-4F48-84C9-01CA0D80286EQ36629277-9F54CDF9-6E02-44E0-8A08-E1ED739D3882Q37206115-6A680EB7-F9B0-4FE6-8350-344D9B9CFD1BQ37687519-E55F2476-1391-45E2-B3B8-639837632381Q37696715-DD39FF39-D017-4456-89E5-DA2061BC7C9AQ37833893-9CCF4F54-23D3-4374-80E3-981DE3CCDA1AQ37869152-C8A7FA40-388A-4B75-968C-C404AC19E1ACQ37954363-446BA53A-4AA0-437F-971A-14C0379BF3FEQ38144973-535C8DF7-3DE8-41C5-80BD-54739FAD457FQ38155957-C57BF7E3-338A-4FAD-8FAF-7023E16393FFQ38169198-B3B22481-A5F4-4166-8C99-3D1702E15104Q38780967-78D1A39F-B695-43BE-B01E-CB3E602691AEQ38856226-C9276413-F2B4-47DA-95D1-01775B4A2CC3Q39185214-61BB8F7D-E1E0-4281-896B-D9804BD06625Q39486061-AAA8B06B-4094-4F04-952C-06901E4F45E1Q39539195-8285AFDF-AD36-42F3-92FF-DA08A9F7477AQ41471275-CFFEF3A9-A722-4048-B257-D7C9EE0AEE4AQ41835379-93CDEE34-0CA5-41A5-8ECE-AFAB24C38297Q43239778-364EA135-990B-4EF5-BA2C-442382D880BBQ44028421-72E0636A-7B99-41F8-87BB-28F5FBDA8FA8Q45036817-DCB2BA85-0872-4406-9D12-F1E8E2BE021FQ54189934-5022D14D-6C3B-4E72-8096-EF233B678360
P2860
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@ast
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@en
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@nl
type
label
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@ast
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@en
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@nl
prefLabel
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@ast
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@en
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.
@nl
P2093
P2860
P1476
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
@en
P2093
Fabio Candotti
John J O'Shea
Luigi D Notarangelo
Matthew Husa
Sigrun R Hofmann
P2860
P304
P356
10.1111/J.0105-2896.2005.00220.X
P50
P577
2005-02-01T00:00:00Z